Publications

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Journal article

Ogbe A. et al, (2022), JCI Insight, 7

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination

Journal article

Sharpe HR. et al, (2022), JCI Insight

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire

Journal article

Swanson PA. et al, (2021), Science Translational Medicine, 13

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.

Journal article

Bosaeed M. et al, (2021), The Lancet. Microbe

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Journal article

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.

Journal article

Swanson PA. et al, (2021), medRxiv

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Journal article

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Journal article

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Journal article

Datoo MS. et al, (2021), Lancet (London, England), 397, 1809 - 1818

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Frater J. et al, (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Journal article

Emary KRW. et al, (2021), The Lancet, 397, 1351 - 1362

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Journal article

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Journal article

Emary KRW. et al, (2021), SSRN Electronic Journal

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Journal article

Voysey M. et al, (2021), SSRN Electronic Journal

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Journal article

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Journal article

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)

Internet publication

Folegatti PM. et al, (2020), 396, 1884 - 1884

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Journal article

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993